| Name | Title | Contact Details |
|---|
BME designs, manufactures and markets memory metal implants used in orthopaedic reconstructive surgery and fracture management.
Headquartered in Waterloo, Iowa, VGM is a 100 percent employee-owned company providing business and professional services to thousands of business customers across North America. Services include group purchasing, commercial insurance, management of healthcare services and networks in post-acute cases, healthcare distribution direct to patient homes, specialty consulting, on-line education, digital, print and traditional marketing and more. VGM employs more than 1000 people across 30 states and Canada. Approximately 875 people work in the Waterloo offices and the remainder work in one of VGM`s eight offices outside of Waterloo or work from home. VGM has been named the Top Workplace in Iowa on multiple occasions and is proud of its role in the communities in which it serves.
Medevco is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Global Health Strategies (GHS) is an international consulting company that specializes in global health communications, advocacy, research and strategy. We focus on public health issues that impact developing nations and emerging markets. Our clients include leading foundations, industry, NGOs, government agencies, academic institutions and product development. Our work is driven by a passion for improving the health and wellbeing of individuals and communities around the world. We offer the skills, knowledge and goal-driven efficiency to enhance our clients` efforts to address some of the world’s toughest health challenges, including HIV/AIDS, tuberculosis, malaria, polio eradication, sexual and reproductive health and vaccines. GHS has offices in New York, New Delhi, Rio de Janeiro and Beijing, and supports work in countries in Africa, Asia, Europe and the Americas.